PKCβ inhibitor 1 是有效的，ATP 竞争性和选择性 PKCβ 抑制剂，对人 PKCβ1 和 PKCβ2 的 IC₅₀ 分别为 21 和 5 nM。与 PKCβ2 相比，PKCβ inhibitor 1 对其他 PKC 同工酶 (PKCα、PKCγ 和 PKCε) 具有 60 倍以上的选择性。

PKCβ inhibitor 1 is a potent, ATP-competitive, and selective PKCβ inhibitor with IC 50 s of 21 and 5 nM for human PKCβ1 and PKCβ2, respectively. PKCβ inhibitor 1 exhibits selectivity of more than 60-fold in favor of PKCβ2 relative to other PKC isozymes (PKCα, PKCγ, and PKCε).

Solid

human PKCβ1 21 nM (IC50) human PKCβ2 5 nM

PKCβ inhibitor 1 (0-30 μM; 48 hours) suppresses tumor cell proliferation in a time- and dose-dependent manner.
PKCβ inhibitor 1 (14 μM; 2-48 hours) induces apoptosis in 2F7 cells.
PKCβ inhibitor 1 (15 μM; 2-48 hours) inhibits cell cycle progression in 2F7 and BCBL-1 cells.
PKCβ (15 or 14 μM, respectively; 2-48 hours) inhibitor 1 reduces the expression of phospho-PKCβ in BCBL-1 and 2F7 cells.
PKCβ inhibitor 1(0-48 hours) suppresses GSK3β, mTOR, and S6 phosphorylation. has not independently confirmed the accuracy of these methods. They are for reference only.

Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years；4°C 2 years

[1]. Tanaka M, et al. Synthesis of anilino-monoindolylmaleimides as potent and selective PKCbeta inhibitors. Bioorg Med Chem Lett. 2004 Oct 18;14(20):5171-4.
[2]. Saba NS, et al. Protein kinase C-beta inhibition induces apoptosis and inhibits cell cycle progression in acquired immunodeficiency syndrome-related non-hodgkin lymphoma cells. J Investig Med. 2012 Jan;60(1):29-38.

In Vitro: DMSO : 250 mg/mL (607.59 mM; Need ultrasonic)配制储备液